Prostate Cancer Detection Rate of Targeted Biopsies With PCaVision

NACompletedINTERVENTIONAL
Enrollment

467

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

August 15, 2025

Study Completion Date

August 15, 2025

Conditions
Prostate Cancer
Interventions
DIAGNOSTIC_TEST

3D multi-parametric ultrasound targeted biopsy pathway using PcaVision

The procedure of 3D multiparametric ultrasound consists of 3 components: (1) intravenous administration of ultrasound contrast; (2) rectal multi-parametric ultrasound imaging; (3) PCaVision: artificial intelligence algorithm analyzing the images.

DIAGNOSTIC_TEST

MRI targeted biopsy pathway

MRI sequences will include at least T1-weighted, T2-weighted, Diffusion-weighted imaging (DWI) and calculation of apparent diffusion coefficient (ADC) maps. Scoring of suspicion will be performed using the European Society of Urogenital Radiology (ESUR) PI-RADS standardized scoring system. All lesions will be marked and delineated for MRI-TRUS fusion 3D multiparametric ultrasound (mpUS).

Trial Locations (5)

Unknown

Amsterdam UMC - location VUmc, Amsterdam

Andros Clinics, Baarn

Spaarne Gasthuis, Hoofddorp

St. Antonius, Nieuwegein

Fransiscus Gasthuis, Rotterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Angiogenesis Analytics

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT06281769 - Prostate Cancer Detection Rate of Targeted Biopsies With PCaVision | Biotech Hunter | Biotech Hunter